Gadolinium oxide nanoparticles as potential multimodal imaging and therapeutic agents

Current Topics in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 422-433

  Kim, Tae Jeong ^a   Chae, Kwon Seok ^a   Chang, Yongmin ^b   Lee, Gang Ho ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Gadolinium oxide nanoparticle; MRI; Multimodal imaging; Therapeutic agent

Indexed keywords

ALBUNEX; CONTRAST MEDIUM; DRUG CARRIER; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; IOPROMIDE; IOVERSOL; LACTOBIONIC ACID; MAGNETIC NANOPARTICLE; NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; COMPUTED TOMOGRAPHY SCANNER; DRUG RELEASE; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HEPATOBILIARY DISEASE; HUMAN; HYDRODYNAMICS; INFRARED SPECTROSCOPY; MOLECULAR IMAGING; NEUTRON THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL CIRCULATION; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY; URINARY EXCRETION;

ANIMALS; FLUORESCENT DYES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, FLUORESCENCE; MULTIMODAL IMAGING; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878807142     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313040003     Document Type: Article

References (94)

1. nd ed.; Lippincott Williams & Wilkins: New York, 2004.
2. Geraldes, C. F. G. C.; Laurent, S. Classification and basic propertiesof contrast agents for magnetic resonance imaging. ContrastMedia Mol. Imaging, 2009, 4, 1-23.
3. Strijkers, G. J.; Mulder, W. J. M.; van Tilborg, G. A. F.; Nicolay, K. MRI contrast agents: current status and future perspectives. Anti-Cancer Agents Med. Chem., 2007, 7, 291-305.
4. Lauffer, R. B. Paramagnetic metal complexes as water proton relaxationagents for NMR imaging: theory and design. Chem. Rev.,1987, 87, 901-927.
5. Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, andapplications. Chem. Rev., 1999, 99, 2293-2352.
6. Reimer, P.; Balzer, T. Ferucarbotran (Resovist): a new clinicallyapproved RES-specific contrast agent for contrast-enhanced MRIof the liver: properties, clinical development, and applications. Eur.Radiol., 2003, 13, 1266-1276.
7. Jung, C. W.; Jacobs, P. Physical and chemical properties of superparamagneticiron oxide MR contrast agents: ferumoxides, ferumoxtran,ferumoxsil. Magn. Reson. Imaging, 1995, 13 (5), 661-674.
8. Lodhia, J.; Mandarano, G.; Ferris, N. J.; Eu, P.; Cowell, S. F. Developmentand use of iron oxide nanoparticles (Part 1): synthesis ofiron oxide nanoparticles for MRI. Biomed. Imaging Interv. J.,2010, 6 (2), e12+11 pages
9. Mendonca-Dias, M. H.; Gaggelli, E.; Lauterbur, P. C. Paramagneticcontrast agents in nuclear magnetic resonance medical imaging.Semin. Nucl. Med., 1983, 13 (4), 364-376.
10. Silva, A. C.; Lee, J. H.; Aoki, I.; Koretsky, A. P. Manganeseenhancedmagnetic resonance imaging (MEMRI): methodologicaland practical considerations. NMR Biomed., 2004, 17, 532-543.
11. Crossgrove, J.; Zheng, W. Manganese toxicity upon overexposure.NMR Biomed., 2004, 17, 544-553.
12. Goldman, M. R.; Brady, T. J.; Pykett, I. L.; Burt, C. T.; Buonanno, F. S.; Kistler, J. P.; Newhouse, J. H.; Hinshaw, W. S.; Pohost, G.M. Quantification of experimental myocardial infarction usingnuclear magnetic resonance imaging and paramagnetic ion contrastenhancement in excised canine hearts. Circulation, 1982, 66, 1012-1016.
13. Thomsen, H. S. Nephrogenic systemic fibrosis: a serious late adversereaction to gadodiamide. Eur. Radiol., 2006, 16, 2619-2621.
14. Beers, B. E. V.; Sempoux, C.; Materne, R.; Delos, M.; Smith, A.M. Biodistribution of ultrasmall iron oxide particles in the rat liver.J. Magn. Reson. Imaging, 2001, 13, 594-599.
15. Weissleder, R.; Elizondo, G.; Wittenberg, J.; Rabito, C. A.; Bengele, H. H.; Josephson, L. Ultrasmall superparamagnetic ironoxide: characterization of a new class of contrast agents for MRimaging. Radiology, 1990, 175, 489-493.
16. Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med.,1999, 341, 1986-1995.
17. Xu, W.; Kattel, K.; Park, J. Y.; Chang, Y.; Kim, T. J.; Lee, G. H. Paramagnetic nanoparticle T1 and T2 MRI contrast agents. Phys.Chem. Chem. Phys., 2012, 14, 12687-12700.
18. Park, J. Y.; Choi, E. S.; Baek, M. J.; Lee, G. H.; Woo, S.; Chang, Y. Water-soluble ultra small paramagnetic or superparamagneticmetal oxide nanoparticles for molecular MR imaging. Eur. J.Inorg. Chem., 2009, 2477-2481.
19. Choi, E. S.; Park, J. Y.; Baek, M. J.; Xu, W.; Kattel, K.; Kim, J. H.; Lee, J. J.; Chang, Y.; Kim, T. J.; Bae, J. E.; Chae, K. S.; Suh, K. J.; Lee, G. H. Water-soluble ultra-small manganese oxide surfacedoped gadolinium oxide (Gd2O3@MnO) nanoparticles for MRIcontrast agent. Eur. J. Inorg. Chem., 2010, 4555-4560.
20. Park, J. Y.; Baek, M. J.; Choi, E. S.; Woo, S.; Kim, J. H.; Kim, T.J.; Jung, J. C.; Chae, K. S.; Chang, Y.; Lee, G. H. Paramagnetic ultrasmallgadolinium oxide nanoparticles as advanced T1 MRI contrastagent: account for large longitudinal relaxivity, optimal particlediameter, and in vivo T1 MR images. ACS Nano, 2009, 3, 3663-3669.
21. Engström, M.; Klasson, A.; Pedersen, H.; Vahlberg, C.; Käll, P.-O.; Uvdal, K. High proton relaxivity for gadolinium oxide nanoparticles. Magn. Reson. Mater. Phys., 2006, 19, 180-186.
22. Fortin, M. A.; Petoral Jr, R. M.; Söderlind, F.; Klasson, A.; Engström, M.; Veres, T.; Käll, P. O.; Uvdal, K. Polyethylene glycolcoveredultra-small Gd2O3 nanoparticles for positive contrast at 1.5T magnetic resonance clinical scanning. Nanotechnology, 2007, 18,395501(9 pages).
23. 3+-doped Gd2O3 nanocrystals:a bifunctional material with combined fluorescent labelingand MRI contrast agent properties. J. Phys. Chem. C, 2009, 113,6913-6920.
24. Ahrén, M.; Selegård, L.; Klasson, A.; Söderlind, F.; Abrikossova, N.; Skoglund, C.; Bengtsson, T.; Engström, M.; Käll, P-O.; Uvdal, K. Synthesis and characterization of PEGylated Gd2O3 nanoparticlesfor MRI contrast enhancement. Langmuir, 2010, 26, 5753-5762.
25. Guay-Bégin, A.-A.; Chevallier, P.; Faucher, L.; Turgeon, S.; Fortin, M.-A. Surface modification of gadolinium oxide thin films andnanoparticles using poly(ethylene glycol)-phosphate. Langmuir,2012, 28 (1), 774-782.
26. Bridot, J.-L.; Faure, A.-C.; Laurent, S.; Rivière, C.; Billotey, C.; Hiba, B.; Janier, M.; Josserand, V.; Coll, J.-L.; Elst, L. V.; Muller, R.; Roux, S.; Perriat, P.; Tillement, O. Hybrid gadolinium oxidenanoparticles: multimodal contrast agents for in vivo imaging. J.Am. Chem. Soc., 2007, 129, 5076-5084.
27. Lee, G. H.; Chang, T.; Kim, T.-J. Blood-pool and targeting MRIcontrast agents: from Gd-chelates to Gd-nanoparticles. Eur. J.Inorg. Chem., 2012, 1924-1933.
28. McDonald, M. A.; Watkin, K. L. Investigations into the physicochemicalproperties of dextran small particulate gadolinium oxidenanoparticles. Acad. Radiol., 2006, 13, 421-427.
29. Yang, J.; Lee, C.-H.; Park, J.; Seo, S.; Lim, E.-K.; Song, Y. J.; Suh, J.-S.; Yoon, H.-G.; Huh, Y.-M.; Haam, S. Antibody conjugatedmagnetic PLGA nanoparticles for diagnosis and treatment of breastcancer. J. Mater. Chem., 2007, 17, 2695-2699.
30. Irvine, D. J. Drug delivery: one nanoparticle, one kill. Nat. Mater.,2011, 10, 342-343.
31. Tian, G.; Gu, Z.; Liu, X.; Zhou, L.; Yin, W.; Yan, L.; Jin, S.; Ren, W.; Xing, G.; Li, S.; Zhao, Y. Facile fabrication of rare-earthdopedGd2O3 hollow spheres with upconversion luminescence, magnetic resonance, and drug delivery properties. J. Phys. Chem.C, 2011, 115, 23790-23796.
32. Huxford, R. C.; Rocca, J. D.; Lin, W. Metal-organic frameworks aspotential drug carriers. Curr. Opinion Chem. Biol., 2010, 14, 262-268.
33. Valeur, B. Molecular Fluorescence: Principles and Applications,Wiley-VCH: Weinheim, 2002.
34. de Silva, A. P.; Gunaratne, H. Q. N.; Gunnlaugsson, T.; Huxley, A.J. M.; McCoy, C. P.; Rademacher, J. T.; Rice, T. E. Signaling recognitionevents with fluorescent sensors and switches. Chem. Rev.,1997, 97, 1515-1566.
35. Johnsson, N.; Johnsson, K. Chemical tools for biomolecular imaging.ACS Chem. Biol., 2007, 2, 31-38.
36. Kovar, J. L.; Simpson, M. A.; Schutz-Geschwender, A.; Olive, D.M. A systematic approach to the development of fluorescent contrastagents for optical imaging of mouse cancer models. Anal. Biochem.,2007, 367, 1-12.
37. Yu, S.-B.; Watson, A. D. Metal-based X-ray contrast media.Chem. Rev., 1999, 99, 2353-2377.
38. Wharton, T.; Wilson, L. J. Highly-iodinated fullerene as a contrastagent for X-ray imaging. Bioorg. Med. Chem., 2002, 10, 3545-3554.
39. Nelson, R. C.; Chezmar, J. L.; Peterson, J. E.; Bernardino, M. E.Contrast-enhanced CT of the liver and spleen: comparison of ionicand nonionic contrast agents. AJR, 1989, 153, 973-976.
40. Hooker, J. M. Modular strategies for PET imaging agents. Curr.Opin. Chem. Biol., 2010, 14, 105-111.
41. Anderson, C. J.; Welch, M. J. Radiometal-labeled agents (nontechnetium)for diagnostic imaging. Chem. Rev., 1999, 99, 2219-2234.
42. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Coordinatingradiometals of copper, gallium, indium, yttrium, and zirconiumfor PET and SPECT imaging of disease. Chem. Rev., 2010,110, 2858-2902.
43. 99mTc-labeled small peptides as diagnosticradiopharmaceuticals. Chem. Rev., 1999, 99, 2235-2268.
44. Bloem, J. L.; Wondergem, J. Gd-DTPA as a contrast agent in CT. Radiology, 1989, 171, 578-579.
45. Kawano, T.; Ishijima, H.; Nakajima, T.; Aoki, J.; Endo, K. Gd-DTPA: a possible alternative contrast agent for use in CT duringintraarterial administration. J. Comput. Assist. Tomogr., 1999, 23,939-940.
46. Cheung, E. N. M.; Alvares, R. D. A.; Oakden, W.; Chaudhary, R.; Hill, M. L.; Pichaandi, J.; Mo, G. C. H.; Yip, C.; Macdonald, P. M.; Stanisz, G. J.; van Veggel, F. C. J. M.; Prosser, R. S. Polymerstabilizedlanthanide fluoride nanoparticle aggregates as contrastagents for magnetic resonance imaging and computed tomography. Chem. Mater., 2010, 22, 4728-4739.
47. Weast, R. C. ed., CRC Handbook of Chemistry and Physics, 65thed.; CRC Press, page B235-B319, 1984-1985.
48. McDonald, M. A.; Watkin, K. L. Small particulate gadoliniumoxide and gadolinium albumin microspheres as multimodalcontrast and therapeutic agents. Invest. Radiol., 2003, 38, 305-310.
49. Watkin, K. L.; McDonald, M. A. Multi-modal contrast agents: afirst step. Acad. Radiol., 2002, 9, S285-S289.
50. Choi, H. S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Ipe, B.I.; Bawendi, M. G.; Frangioni, J. V. Renal clearance of quantumdots. Nat. Biotechnology, 2007, 25 (10), 1165-1170.
51. Moon, R. M.; Koehler, W. C. Magnetic properties of Gd2O3. Phys.Rev. B, 1975, 11, 1609-1622.
52. Lal, H.B.; Pratap, V.; Kumar, A. Magnetic susceptibility of heavyrare-earth sesquioxides. Pramana 1978, 10 (4), 409-412.
53. Wolf, W. P.; Meissner, H.; Catanese, C. A. Magnetic properties ofrare earth hydroxides. J. Appl. Phys., 1968, 39 (2), 1134-1136.
54. Arajs, S.; Colvin, R. V. Magnetic susceptibility of gadolinium anddysprosium sesquioxides at elevated temperatures. J. Appl. Phys.,1962, 33 (8), 2517-2519.
55. Baek, M. J.; Park, J. Y.; Xu, W.; Kattel, K.; Kim, H. G.; Lee, E. J.; Patel, A. K.; Lee, J. J.; Chang, Y.; Kim, T. J.; Bae, J. E.; Chae, K.S.; Lee, G. H. Water-soluble MnO nanocolloids for a molecular T1MR imaging: a facile one-pot synthesis, in vivo T1 MR images, andaccount for relaxivities. ACS Appl. Mater. Interfaces, 2010, 2 (10),2949-2955.
56. Moran, G. R.; Pekar, J.; Bartolini, M.; Chettle, D. R.; McNeill, F.; Scott, A.; Gibbons, J.; Prato, F. S. An investigation of the toxicityof gadolinium based MRI contrast agents. Proc. Intl. Soc. Mag.Reson. Med., 2002, 10.
57. Klaassen, C. D.; Watkins III, J. B. Mechanisms of bile formation,hepatic uptake, and biliary excretion. Pharmacol. Rev., 1984, 36, 1-67.
58. Xu, W.; Park, J. Y.; Kattel, K.; Bony, B. A.; Heo, W. C.; Jin, S.; Park, J. W.; Chang, Y.; Do, J. Y.; Chae, K. S.; Kim, T. J.; Park, J.A.; Kwak, Y. W.; Lee, G. H. A T1, T2 magnetic resonance imaging(MRI)-fluorescent imaging (FI) by using ultrasmall mixedgadolinium-europium oxide nanoparticles. New J. Chem., 2012, 36,2361-2367.
59. Chang, C.; Mao, D. Thermal dehydration kinetics of a rare earthhydroxide, Gd(OH)3. Int. J. Chem. Kinet., 2007, 39, 75-81.
60. Söderlind, F.; Pedersen, H.; Petoral Jr., R. M.; Käll, P.-O.; Uvdal, K. Synthesis and characterization of Gd2O3 nanocrystals functionalizedby organic acids. J. Colloid Interface Sci., 2005, 288, 140-148.
61. Kattel, K.; Park, J. Y.; Xu, W.; Kim, H. G.; Lee, E. J.; Bony, B. A.; Heo, W. C.; Lee, J. J.; Jin, S.; Baek, J. S.; Chang, Y.; Kim, T. J.; Bae, J. E.; Chae, K. S.; Lee, G. H. A facile synthesis, in vitro and invivo MR studies of D-glucuronic acid-coated ultrasmall Ln2O3 (Ln= Eu, Gd, Dy, Ho, and Er) nanoparticles as a new potential MRIcontrast agent. ACS Appl. Mater. Interfaces, 2011, 3, 3325-3334.
62. Sakai, N.; Zhu, L.; Kurokawa, A.; Takeuchi, H.; Yano, S.; Yanoh, T.; Wada, N.; Taira, S.; Hosokai, Y.; Usui, A.; Machida, Y.; Saito, H.; Ichiyanagi, Y. Synthesis of Gd2O3 nanoparticles for MRI contrastagents. J. Phys.: Conf. Ser., 2012, 352, 012008+6 pages.
63. Roberts, D.; Zhu, W. L.; Frommen, C. M.; Rosenzweig, Z. Synthesis of gadolinium oxide magnetoliposomes for magneticresonance imaging. J. Appl. Phys., 2000, 87, 6208-6210.
64. Miyawaki, J.; Yudasaka, M.; Imai, H.; Yorimitsu, H.; Isobe, H.; Nakamura, E.; Iijima, S. Synthesis of ultrafine Gd2O3 nanoparticlesinside single-wall carbon nanohorns. J. Phys. Chem. B, 2006, 110,5179-5181.
65. Sitharaman, B.; Kissell, K. R.; Hartman, K. B.; Tran, L. A.; Baikalov, A.; Rusakova, I.; Sun, Y.; Khant, H. A.; Ludtke, S. J.; Chiu, W.; Laus, S.; Tóth, É.; Helm, L.; Merbach, A. E.; Wilson, L.J. Superparamagnetic gadonanotubes are high-performance MRIcontrast agents. Chem. Comm. 2005, 3915-3917.
66. Li, I.-F.; Su, C.-H.; Sheu, H.-S.; Chiu, H.-C.; Lo, Y.-W.; Lin, W.-T.; Chen, J.-H.; Yeh, C.-S. Gd2O(CO3)2.H2O particles andthe corresponding Gd2O3: synthesis and applications of magneticresonance contrast agents and template particles for hollow spheresand hybrid composites. Adv. Funct. Mater., 2008, 18, 766-776.
67. Hu, K.-W.; Jhang, F.-Y.; Su, C.-H.; Yeh, C.-S. Fabrication ofGd2O(CO3)2.H2O/silica/gold hybrid particles as a bifunctional agentfor MR imaging and photothermal destruction of cancer cells. J.Mater. Chem., 2009, 19, 2147-2153.
68. Hifumi, H.; Yamaoka, S.; Tanimoto, A.; Citterio, D.; Suzuki, K. Gadolinium-based hybrid nanoparticles as a positive MR contrastagent. J. Am. Chem. Soc., 2006, 128, 15090-15091.
69. Evanics, F.; Diamente, P. R.; van Veggel, F. C. J. M.; Stanisz, G.J.; Prosser, R. S. Water-soluble GdF3 and GdF3/LaF3 nanoparticlesphysicalcharacterization and NMR relaxation properties. Chem.Mater., 2006, 18, 2499-2505.
70. Johnson, N. J. J.; Oakden, W.; Stanisz, G. J.; Prosser, R. S.; vanVeggel, F. C. J. M. Size-tunable, ultrasmall NaGdF4 nanoparticles:insight into their T1 MRI contrast enhancement. Chem. Mater.,2011, 23, 3714-3722.
71. 3+-doped Gd2O3 nanoparticles as a luminescent and T1contrast agent for stem cell labeling. Contrast Media Mol. Imaging,2010, 5, 1-7.
72. Li, I.-F.; Yeh, C.-S. Synthesis of Gd doped CdSe nanoparticles forpotential optical and MR imaging applications. J. Mater. Chem.,2010, 20, 2079-2081.
73. 3+ hollow spheres: synthesis and magnetic andluminescent properties. Inorg. Chem., 2011, 50, 10608-10613.
74. Rocca, J. D.; Lin, W. Nanoscale metal-organic frameworks: magneticresonance imaging contrast agents and beyond. Eur. J. Inorg.Chem., 2010, 24, 3725-3734.
75. Duckworth, O. W.; Martin, S. T. Surface complexation and dissolutionof hematite by C1-C6 dicarboxylic acids at pH = 5.0. Geochim.Cosmochim. Acta, 2001, 65 (23), 4289-4301.
76. Hug, S. J.; Bahnemann, D. Infrared spectra of oxalate, malonateand succinate adsorbed on the aqueous surface of rutile, anataseand lepidocrocite measured with in situ ATR-FTIR. J. ElectronSpectro. Related Phenomena, 2006, 150, 208-219.
77. Hug, S. J.; Sulzberger, B. In situ fourier transform infrared spectroscopicevidence for the formation of several different surface complexesof oxalate on TiO2 in the aqueous phase. Langmuir, 1994,10, 3587-3597.
78. Mendive, C. B.; Bredow, T.; Blesa, M. A.; Bahnemann, D. W. ATR-FTIR measurements and quantum chemical calculations concerningthe adsorption and photoreaction of oxalic acid on TiO2.Phys. Chem. Chem. Phys., 2006, 8, 3232-3247.
79. McDonald, M. A.; Watkin, K. L. Investigations into the structureand magnetic properties of dextran small particulate gadoliniumoxide nanoparticles. Proc. Intl. Soc. Mag. Reson. Med., 2004, 11.
80. Xu, W.; Park, J. Y.; Kattel, K.; Ahmad, Md. W.; Bony, B. A.; Heo, W. C.; Jin, S.; Park, J. W.; Chang, Y.; Kim, T. J.; Park, J. A.; Do, J.Y.; Chae, K. S.; Lee, G. H. Fluorescein-polyethyleneimine coatedgadolinium oxide nanoparticles as T1 magnetic resonance imaging(MRI)- cell labeling (CL) dual agents. RSC Adv., 2012, 2, 10907-10915.
81. Gierda, D. A.; Bae, K. T. Gadolinium as a CT contrast agent:assessment in a procine model. Radiology, 1999, 210, 829-834.
82. Quinn, A. D.; O'Hare, N. J.; Wallis, F. J.; Wilson, G. F. Gd-DTPA:an alternative contrast medium for CT. J. Comput. Assist. Tomogr.,1994, 18, 634-636.
83. Wells, P. N. T. Ultrasound imaging. Phys. Med. Biol., 2006, 51,R83-R98.
84. Barnhart, J.; Levene, H.; Elaine, V.; Maniquis, J.; Fernandez, J.; Rice, S.; Jablonski, E.; Gjøen, T.; Tolleshauq, H. Charateristics ofalbunex: air-filled albumin microshperes for echocardiographycontrast enhancement. Invest. Radiol., 1990, 25, S162-S164.
85. Stasio, G. D.; Rajesh, D.; Casalbore, P.; Daniels, M. J.; Erhardt, R.J.; Frazer, B. H.; Wiese, L. M.; Richter, K. L.; Sonderegger, B. R.; Gilbert, B.; Schaub, S.; Cannara, R. J.; Crawford, J. F.; Gilles, M.K.; Tyliszczak, T.; Fowler, J. F.; Larocca, L. M.; Howard, S. P.; Mercanti, D.; Mehta, M. P.; Pallini, R. Are gadolinium contrastagents suitable for gadolinium neutron capture therapy?. Neurological Research, 2005, 27, 387-398.
86. Tokumitsu, H.; Ichikawa, H.; Fukomori, Y.; Block, L. H.Preparation of gadopentetic acid-loaded chitosan microparticles forgadolinium neutron-capture therapy of cancer by a novel emulsiondropletcoalescence technique. Chem. Pharm. Bull. 1999, 47, 838-842.
87. Bridot, J.-L.; Dayde, D.; Rivière, C.; Mandon, C.; Billotey, C.; Lerondel, S.; Sabattier, R.; Cartron, G.; Pape, A. L.', Blondiaux, G.; Janier, M.; Perriat, P.; Roux, S.; Tillement, O. Hybrid gadoliniumoxide nanoparticles combining imaging and therapy. J. Mater.Chem. 2009, 19, 2328-2335.
88. Kattel, K.; Park, J. Y.; Xu, W.; Kim, H. G.; Lee, E. J.; Bony, B. A.; Heo, W. C.; Chang, Y.; Kim, T. J.; Do, J. Y.; Chae, K. S.; Kwak, Y. W.; Lee, G. H. Water-soluble ultrasmall Eu2O3 nanoparticles asa fluorescent imaging agent: in vitro and in vivo studies. Coll. Surf.A: Physicochem. Eng. Aspects, 2012, 394, 85-91.
89. Yoon, Y.; Lee, B.-I.; Lee, K. S.; Heo, H.; Lee, J. H.; Byeon, S.-H.; Lee, I. S. Fabrication of a silica sphere with fluorescent and MRcontrasting GdPO4 nanoparticles from layered gadolinium hydroxide.Chem. Comm., 2010, 46, 3654-3656.
90. Wakefield, G.; Keron, H. A.; Dobson, P. J.; Hutchison, J. L. Synthesisand properties of sub-50-nm europium oxide nanoparticles.J. Colloid Interface Sci., 1999, 215, 179-182.
91. 3+-doped Gd2O3 phosphor fine spherical powders usingpolyol-mediated synthesis. Appl. Phys. A, 2005, 81, 1385-1391.
92. Taylor-Pashow, K. M. L.; Della Rocca, J.; Xie, Z.; Trans, S.; Lin, W. Postsynthetic modifications of iron-carboxylate nanoscalemetal-organic frameworks for imaging and drug delivery. J. Am.Chem. Soc., 2009, 131, 14261-14263.
93. Horcajada, P.; Serre, C.; Vallet-Regi, M.; Sebban, M.; Taulelle, F.; Ferey, G. Metal-organic frameworks as efficient materials for drugdelivery. Angew. Chem. Int. Ed., 2006, 45, 5974-5978.
94. Reiter, W. J.; Pott, K. M.; Taylor, K. M. L.; Lin, W. Nanoscalecoordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc., 2008, 130, 11584-11585.